[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100430646":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":34,"locations":43,"responsibleParty":95,"collaborators":99,"id":102,"slug":29,"hasResults":103,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":103,"sex":109,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":29,"studyType":115,"phases":116,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":45,"whyStopped":29,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Acetazolamide","ACTIVE_COMPARATOR","acetazolamide capsules",[13],"Drug: Acetazolamide",{"label":15,"type":10,"description":16,"interventionNames":17},"Placebo","Identical gelatin capsules",[18],"Drug: Placebo",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","ACZ 250 mg\u002Fday in gelatin capsules will be administered initially and increased over 7-10 days to 2g\u002Fday.",[9],[25],"Diamox",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"Identical gelatin capsules will be prepared by filling with inert excipients.",[15],null,[31],{"name":32,"affiliation":5,"role":33},"Vishwajit L Nimgaonkar, M.D., Ph.D.","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":29,"email":38},"CONTACT","412-246-6356","vishwajitNL@upmc.edu",{"name":40,"role":36,"phone":41,"phoneExt":29,"email":42},"Maribeth A Wesesky, BPS","4122957017","weseskyma@upmc.edu",[44,71],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"RECRUITING","Pittsburgh","Pennsylvania","15213","United States",{"type":51,"coordinates":52},"Point",[53,54],-79.99589,40.44062,{"lat":54,"lon":53},[57,59,62,64,65,67,69],{"name":40,"role":36,"phone":58,"phoneExt":29,"email":42},"412-295-7017",{"name":60,"role":61,"phone":29,"phoneExt":29,"email":29},"Satish Iyengar, Ph.D.","SUB_INVESTIGATOR",{"name":63,"role":61,"phone":29,"phoneExt":29,"email":29},"Konasale Prasad, M.D.",{"name":40,"role":61,"phone":29,"phoneExt":29,"email":29},{"name":66,"role":61,"phone":29,"phoneExt":29,"email":29},"Ian Conner, M.D.",{"name":68,"role":61,"phone":29,"phoneExt":29,"email":29},"Madhavi K Ganapathiraju, Ph.D.",{"name":70,"role":61,"phone":29,"phoneExt":29,"email":29},"Roy KN Chengappa, M.D.",{"facility":72,"status":45,"city":73,"state":29,"zip":29,"country":74,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"St John's Medical College Hospital","Bangalore","India",{"type":51,"coordinates":76},[77,78],77.59369,12.97194,{"lat":78,"lon":77},[81,85,89,91,93],{"name":82,"role":36,"phone":83,"phoneExt":29,"email":84},"Smita N Deshpande, M.D.","(91)- 93126-54702","smitadeshp@gmail.com",{"name":86,"role":36,"phone":87,"phoneExt":29,"email":88},"Triptish Bhatia, Ph.D.","(91)-11-23404363","bhatiatriptish@yahoo.co.in",{"name":90,"role":61,"phone":29,"phoneExt":29,"email":29},"Ashok Mysore, M.D.",{"name":92,"role":61,"phone":29,"phoneExt":29,"email":29},"Anil Kakunje, M.D.",{"name":94,"role":33,"phone":29,"phoneExt":29,"email":29},"Smita Deshpande, M.D.",{"type":96,"investigatorFullName":97,"investigatorTitle":98,"investigatorAffiliation":5,"oldNameTitle":29,"oldOrganization":29},"SPONSOR_INVESTIGATOR","Vishwajit Nimgaonkar, MD PhD","Professor of Psychiatry and Human Genetics",[100],{"name":101,"class":6},"Stanley Medical Research Institute","100430646",false,"NCT04887792","Acetazolamide for Treatment Resistant Schizophrenia","A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia","APTS","Inclusion Criteria:\n\n* Written informed consent.\n* Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).\n* PANSS total score \\> 60 and Score \\> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.\n* Stable dose of antipsychotic drug (APD) for \\> 1 month, continued throughout the study.\n* Not participating in another randomized controlled clinical trial (RCT).\n\nExclusion Criteria:\n\n* Substance abuse in the past month\u002Fdependence past 6 months with the exception of methadone prescribed for opiate withdrawal.\n* History or current medical\u002Fneurological illnesses that may lead to unstable course, e.g., epilepsy.\n* Pregnancy.\n* Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease\u002Fadrenal failure; chronic closed angle-closure glaucoma.\n* Current or prior treatment with ACZ or history of hypersensitivity to ACZ.\n* Intellectual disability as defined in DSM 5.","ALL","18 Years","55 Years",{"count":113,"type":114},60,"ESTIMATED","INTERVENTIONAL",[117,118],"PHASE1","PHASE2","This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.",[121,122],"Schizophrenia","Schizo Affective Disorder",[121,122,124],"acetazolamide","2026-04-06",{"date":127,"type":128},"2026-04-07","ACTUAL",{"date":130,"type":128},"2022-02-01",{"date":132,"type":114},"2026-12-30",{"name":97,"class":6},2]